Covidien LP v. Esch

229 F. Supp. 3d 94, 2017 WL 111918, 2017 U.S. Dist. LEXIS 4083
CourtDistrict Court, D. Massachusetts
DecidedJanuary 11, 2017
DocketCivil Action No. 16-12410-NMG
StatusPublished
Cited by6 cases

This text of 229 F. Supp. 3d 94 (Covidien LP v. Esch) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Covidien LP v. Esch, 229 F. Supp. 3d 94, 2017 WL 111918, 2017 U.S. Dist. LEXIS 4083 (D. Mass. 2017).

Opinion

MEMORANDUM & ORDER

GORTON, J.

This dispute arises out of alleged breaches of an employment agreement and a separation agreement between Covidien LP and Covidien Holding Inc. (“plaintiffs” or “Covidien”), on the one hand, and Brady Esch (“defendant”), Covidien’s former employee, on the other. Plaintiffs allege defendant breached those agreements by 1) assigning rights to three patents to his new company rather than to Covidien and 2) disclosing plaintiffs’ confidential information in the patent applications.

Pending before this Court is plaintiffs’ motion for a preliminary injunction. For the following reasons, plaintiffs motion will be allowed.

I. Background

Covidien is global healthcare company and a manufacturer of medical devices and supplies. At issue in this case are Covi-dien’s Endovenous (“EV”) products, which are used to treat superficial venous disease, commonly known as varicose veins.

A. The NNC Agreement

Brady Esch began working for Covidien in 2009 when Covidien acquired VNUS Technologies, Esch’s employer at the time. In or about December, 2009, Esch entered into a “Non-Competition, Non-Solicitation, and Confidentiality Agreement” (“NNC Agreement”) with Covidien.

The NNC Agreement provides that Esch must disclose to Covidien all “inventions” (defined broadly in the NNC Agreement) created during his employment with Covidien or within one year after leaving the company:

You shall promptly disclose to the Company all Inventions (as defined in Subsection II.B), which are made or conceived by you, either alone or with others, during the term of your employment with ' the Company, whether or not during working hours.... In addition, in order to avoid any dispute as to the date on which Inventions were made or conceived by you, they shall be deemed to have been made or conceived during your employment with the Company if you take affirmative steps to have them reduced to practice either during the term of your employment or within one year after separation from employment. ’

The NNC Agreement further states that Esch “hereby assign[s]” all interest in such inventions to Covidien and that Esch will not disclose any of Covidien’s confidential information.

B. The Separation Agreement

In or about November, 2013, Esch was terminated from Covidien. At that time, he was the Director of Global Marketing for the VNUS business. As part of his termination, Esch signed a “Separation of Employment Agreement and General Release” (“Separation Agreement”).

The Separation Agreement provides in pertinent part, that:

any provisions of [the NNC Agreement] concerning the disclosure or ownership of inventions, methods, processes or improvements shall continue in full force and effect and shall not be superseded by any provision of [the Separation Agreement].

[97]*97The Separation Agreement also states that Esch shall abide by all previous agreements with respect to “non-disclosure of confidential information.”

C. Esch’s Patent Applications

Soon after Esch was terminated from Covidien, he formed his own company called Vencióse, Inc. In March, 2014, Esch filed a provisional patent application 61/970,498 (“ ’498 application”). Along with that patent application, Esch filed a document with the United States Patent and Trademark Office (“USPTO”) purportedly assigning all rights to the ’498 application to Vencióse, Inc.

A year later in March, 2015, Esch and Darius Pryzgoda filed the patent application 14/670,339 (“ ’338 application”), claiming priority to the ’498 application. Esch listed himself, Pryzgoda, Rory Christian and Cody Schlinder as inventors in the application. As with the ’498 application, Esch assigned his rights to the ’338 application to Vencióse.

Also in or about March, 2015, Esch filed a Patent Cooperation Treaty application, PCT/US2015/022849 (“PCT application”) with the USPTO as a receiving office for the World Intellectual Property Organization. Vencióse was listed as the applicant and Esch and Pryzgoda were listed as the inventors.

All three patent applications are directed toward a three-wire catheter system.

D. Procedural History

In November, 2016, Covidien filed a five-count complaint in this Court. In December, 2016, shortly after United States District Judge George A. O’Toole, Jr. recused himself from the action, Covidien filed a motion for a preliminary injunction. This session held a hearing on that motion on January 6, 2016.

Plaintiffs motion is the subject of this, memorandum.

II. Plaintiffs’ Motion for a Preliminary Injunction

A. Personal Jurisdiction

As a threshold matter, defendant avers that this Court lacks personal jurisdiction over him. Although defendant indicates that he plans to file a motion to dismiss for at least, in part, lack of personal jurisdiction and the Court hesitates to address the merits of a hypothetical question, this Court must have personal jurisdiction over the defendant in order to enter the requested injunction. United Elec., Radio & Mach. Workers of Am. v. 163 Pleasant St. Corp., 960 F.2d 1080, 1084 (1st Cir. 1992). Accordingly, the Court will address defendant’s jurisdictional argument in the context of plaintiffs’ motion for a preliminary injunction.

Defendant contends without citation, that there is no personal jurisdiction in this case because 1) plaintiffs’ claim of personal jurisdiction is based on the forum selection and jurisdictional clauses in the two subject agreements and 2) those agreements are void under California law.

In the NNC Agreement, however, defendant consented to personal jurisdiction in federal courts ⅛ Massachusetts. That clause is not subject to any purported policy that California might have with respect to non-compete agreements. Optos, Inc. v. Topcon Med. Sys., Inc., 777 F.Supp.2d 217, 230 (D. Mass. 2011). Moreover, plaintiffs base their claim for a preliminary injunction on the confidentiality and patent assignment clauses not the non-compete provisions. See id. at 229-30 (“[T]he non-solicitation and non-disclosure clauses in the Agreement fall squarely within California’s trade secret exception.”).

[98]*98Defendant also submits that § 4.d of Separation Agreement provides that the forum selection and jurisdictional clauses in the NNC Agreement do not carry over. That argument is unavailing, however, because § 4.d applies to non-solicitation, non-competition, confidentiality and reasonableness, but not to forum selection or jurisdiction.

Accordingly, because defendant has consented to jurisdiction in this Court, the Court concludes that it has personal jurisdiction over defendant.

B. Merits of the Preliminary Injunction

1. Legal Standard

To obtain a preliminary injunction, the moving party must establish 1) a reasonable likelihood of success on the merits, 2) the potential for irreparable harm if the injunction is withheld, 3) a favorable balance of hardships and 4) the effect on the public interest. Jean v. Mass. State Police,

Related

Groma, LLC v. BuildRE, LLC
D. Massachusetts, 2023
Allscripts Healthcare, LLC v. DR/Decision Res., LLC
386 F. Supp. 3d 89 (District of Columbia, 2019)
Covidien LP v. Esch
264 F. Supp. 3d 325 (D. Massachusetts, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
229 F. Supp. 3d 94, 2017 WL 111918, 2017 U.S. Dist. LEXIS 4083, Counsel Stack Legal Research, https://law.counselstack.com/opinion/covidien-lp-v-esch-mad-2017.